In 2020, research of Keppens et al. showed that for the correct detection of secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer (NSCLC), next-generation sequencing-based techniques (NGS) and non-NGS commercial kits were superior to in-house non-next-generation sequencing techniques [54]. Here, EGFR is linked to non-small cell lung carcinoma.